What you need to know about the FDA’s most recent novel drug approvals.
FDA Roundup: Agency Highlights from September 2024
Check out these important FDA updates from the month of September 2024.
Episode 8: Stay in Sync with Innovations in Medication Decision Support
Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.
Schizophrenia Drug Approved by FDA Represents First New Treatment Option in Decades
The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”
FDA Approves Levacetylleucine for Treatment of Niemann-Pick Disease Type C
The approval comes shortly after the FDA approved arimoclomol from Zevra Therapeutics to treat neurological manifestations of the disease in combination with miglustat.
FDA, CDC: E-Cigarette Use Among Youth Continues to Plummet
Initiatives such as media campaigns and legislative rulings by the agencies have likely contributed to the decline.
FDA Approves First Treatment for Niemann-Pick Disease Type C
Zevra Therapeutics said it expects the therapy to be commercially available in the United States in 8 to 12 weeks.
